In this context, the ability of nitazoxanide’s to block STAT-3/JAK-2 signaling offers a new approach for the management of several inflammatory conditions since the anti-inflammatory action of such drugs stems from its ability to interrupt the STAT-3/JAK-2 signaling pathway, which in turn makes it an attractive candidate for the treatment of patients with RA. The gene discussed is STAT3; the disease is rheumatoid arthritis.